Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Directorate Change

8 Apr 2022 07:00

RNS Number : 7005H
Anpario PLC
08 April 2022
 

Anpario plc

("Anpario" or the "Company")

 

Directorate change

 

Anpario, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity has been notified by Ian Hamilton of his intention to resign as Non-Executive Director and Chair of Nomination Committee with effect from 17 April 2022.

 

Ian is due to take the role of Executive Chairman in a dairy robotics business which he has recently funded on its next stage of growth. The company has also gained financial funding from a major private equity fund and this new full-time role means Ian must relinquish other directorships including Anpario.

 

Kate Allum, Chairman, commented:

 

"We wish Ian every success with his new venture, which brings together his last 30 years of experience, and thank him for his contribution to the Company. Ian has built long lasting relationships with Anpario's senior management team which I'm confident will endure and mutually benefit both parties in the future."

 

Ian Hamiton, stated:

 

"Being a member of the Anpario team has been a wonderful experience and I have been impressed by what the business has achieved and its future growth prospects. The business is well positioned for the current market dynamics and is at the centre of the most important platforms: sustainability, animal welfare and farm profitability. I am very disappointed to have to step away from the role but wish Anpario and its staff the very best of success."

 

The search for a replacement will commence in due course and Kate Allum will assume the Chair of Nomination Committee in the interim.

 

 

Anpario plc

Richard Edwards, CEO +44(0) 777 6417 129Marc Wilson, Group Finance Director +44(0) 1909 537380

 

Peel Hunt LLP (NOMAD) +44 (0)20 7418 8900Adrian Trimmings

Andrew Clark

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEASLXEFDAEFA
Date   Source Headline
18th Jun 20267:00 amRNSAGM Statement
11th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
9th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
19th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
15th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
14th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
12th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
11th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
8th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
7th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
6th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
5th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
1st May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20267:00 amRNSLaunch of Share Buyback Programme
10th Apr 202612:00 pmRNSInvestor Presentation via Investor Meet Company
31st Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSHolding(s) in Company
19th Jan 20263:44 pmRNSBlock listing return
19th Jan 20267:00 amRNSFull year trading statement
23rd Sep 20257:00 amRNSChange of Auditor
10th Sep 20257:00 amRNSInterim Results
9th Sep 202511:36 amRNSInvestor Presentation via Investor Meet Company
22nd Jul 20257:00 amRNSJSOP Awards and TVR
17th Jul 20251:15 pmRNSBlock listing return
19th Jun 20252:01 pmRNSResult of AGM
19th Jun 20257:00 amRNSAGM Statement
19th May 20255:33 pmRNSPosting of Annual Report and Notice of AGM
2nd May 20257:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSLaunch of Share Buyback Programme
2nd Apr 20257:00 amRNSAward Exercise, Voting Rights & Director Dealing
31st Mar 20257:00 amRNSFinal Results
26th Mar 20257:00 amRNSUpdate on Timing of Full Year Results Announcement
15th Jan 20257:00 amRNSGrant of options under SAYE Scheme
10th Jan 20257:00 amRNSFull year trading statement
9th Jan 20257:00 amRNSTotal Voting Rights
16th Dec 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
16th Dec 20247:00 amRNSLaunch of SAYE Scheme
29th Nov 20247:00 amRNSTotal Voting Rights
30th Sep 20247:00 amRNSAcquisition of Bio-Vet Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.